Репродуктивная функция у женщин с ревматоидным артритом: влияние заболевания и терапии метотрексатом на уровень антимюллерова гормона

1. Насонов Е.Л., ред. Ревматология. Российские клинические рекомендации. М.: «ГЭОТАР-Медиа», 2017. 456 с.

2. Jawaheer D., Zhu J.L., Nohr E.A., et al. Time to pregnancy among women with rheumatoid arthritis. Arthritis Rheum. 2011; 63(6): 1517–21. doi: 10.1002/art.30327.
3. Clowse M., Chakravarty E., Costenbader K. H., Chambers C., Michaud, K. Effects of infertility, pregnancy loss and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. (Hoboken). 2012; 64(5): 668–74. doi: 10.1002/acr.21593.
4. Brouwer J., Hazes J.M., Laven J.S., Dolhain R.J. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann. Rheum. Dis. 2015; 74(10):1836-41. doi: 10.1136/annrheumdis-2014-205383.
5. Brouwer J., Fleurbaaij R., Hazes J.M., Dolhain, R.J., Laven J. S. Subfertility in rheumatoid arthritis is often unexplained or caused by anovulation. Arthritis Care Res (Hoboken). 2017; 69(8): 1142–9. doi: 10.1002/acr.23124.
6. Andreoli L., Bertsias G.K., Agmon-Levin N., Brown S., Cervera R., Costedoat-Chalumeau N., et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis. 2017; 76(3): 76–85. doi:10.1136/annrheumdis-2016-209770.
7. Van Sinderen M., Menkhorst E., Winship A., Cuman C., Dimitriadis E.Preimplantation human blastocyst-endometrial interactions: the role of inflammatory mediators. Am J Reprod Immunol 2013; 69(5): 427–40. doi: 10.1111/aji.12038.
8. Ince-Askan H., Dolhain R.J. Pregnancy and rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2015; 29(4-5): 580–96. doi: 10.1016/j.berh.2015.07.001.
9. Micu M.C., Micu R., Ostensen M. Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies. Arthritis Care Res. 2011; 63(9):1334-8. doi: 10.1002/acr.20510.
10. Mendonca L.L., Khamashta M.A., Nelson-Piercy C., Hunt B.J., Hughes G.R.Non-steroidal anti- inflammatory drugs as a possible cause for reversible infertility. Rheumatology. 2000; 39(8): 880–2.
11. Saketos M., Sharma N., Santoro N.F. Suppression of the hypothalamic-pituitary-ovarian axis in normal women by glucocorticoids. Biol Reprod. 1993; 49(6): 1270–6.
12. McLaren J.F., Burney R.O., Milki A.A., Westphal L.M., Dahan M.H., Lathi R.B. Effect of methotrexate exposure on subsequent fertility in women undergoing controlled ovarian stimulation. Fertil Steril. 2009; 92: 515–9. doi: 10.1016/j.fertnstert.2008.07.009
13. Brouwer J., Laven, J.S., Hazes J.M., Schipper I., Dolhain R.J. Levels of serum anti-Mullerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res. (Hoboken) 2013; 65(9): 1534-8. doi: 10.1002/acr.22013.
14. Hill M.J., et al. Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location. Fertil. Steril. 2014; 101(2): 413–9. doi: 10.1016/j.fertnstert.2013.10.027.
15. Henes M., et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behcet’s disease and spondyloarthritis on antiMullerian hormone levels. Rheumatology (Oxford) 2015; 54(9): 1709–12. doi: 10.1093/rheumatology/kev124.
16. Sowers M., et al. Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil. Steril. 2010; 94(4): 1482–6. doi: 10.1016/j.fertnstert.2009.07.1674.
17. Manger K., Wildt L., Kalden J.R., Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmunity reviews. 2006; 5(4):269–272.

Поступила 04.02.2020

Принята в печать 07.02.2020